<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637529</url>
  </required_header>
  <id_info>
    <org_study_id>APS003/2020</org_study_id>
    <nct_id>NCT04637529</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain</brief_title>
  <acronym>APS003/2020</acronym>
  <official_title>National, Multicentre, Randomized, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of S (+) - Ibuprofen for Pain Control in Individuals With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apsen Farmaceutica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apsen Farmaceutica S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an&#xD;
      active treatment for pain control in individuals diagnosed with osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)</measure>
    <time_frame>Baseline (day 0) and Week 4 (day 28)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement-I (PGI-I)</measure>
    <time_frame>Week 4 (day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants among the groups to discontinue the trial due to treatment non-tolerability</measure>
    <time_frame>From Baseline (day 0) to Week 4 (day 28)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>S (+) - Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuvix® - ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S (+) - Ibuprofen</intervention_name>
    <description>S (+) - Ibuprofen + placebo of Ibuvix®</description>
    <arm_group_label>S (+) - Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuvix® - ibuprofen</intervention_name>
    <description>Ibuvix® + placebo of S(+) - Ibuprofen</description>
    <arm_group_label>Ibuvix® - ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Patients aged from 18 to 75 with a diagnosis of knee and/or hip osteoarthritis&#xD;
             according to American College of Rheumatology (ACR) criteria.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  Previous history of alcohol or drugs abuse diagnosed by DSM-V;&#xD;
&#xD;
          -  Current or previous history (less than 12 months) of smoking;&#xD;
&#xD;
          -  Have clinically relevant abnormal laboratory results according to medical evaluation;&#xD;
&#xD;
          -  Women who are pregnant, lactating, or positive for β - hCG urine test;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fernanda Martinez, B.Sc.</last_name>
    <phone>+551156448200</phone>
    <phone_ext>8404</phone_ext>
    <email>fernanda.martinez@apsen.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Apsen Farmacêutica S.A.</name>
      <address>
        <city>São Paulo</city>
        <zip>04753-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernanda Martinez, B.Sc.</last_name>
      <phone>+ 55 11 5644-8200</phone>
      <phone_ext>8404</phone_ext>
      <email>fernanda.martinez@apsen.com.br</email>
    </contact>
    <investigator>
      <last_name>Dr. Mauro Acir Crippa Junior, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonsteroidal anti-inflammatory</keyword>
  <keyword>Pain</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Anti-inflammatory</keyword>
  <keyword>Pain control</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Pain relief</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

